ARCHIVES

FDA Approves NDA For Mylan’s Paclitaxel For Ovarian And Breast Cancer Treatment.

This article is from The Cancer Letter archive.

Vol. 27 No. 30 | July 27, 2001

Download PDF Visit The Full Archive

Related Articles

COG Begins Phase III Trial To Prevent Hearing Loss

May 30, 2008

ASCO Advises KRAS Testing In Patients With Metastatic Colorectal Cancer

January 30, 2009

Trials Approved by NCI CTEP For the Month of January

January 27, 2012

Translplants Not Best Choice in Subset of ALL Patients

April 27, 2012

Sullivan Confirmation Hearing Set For Feb. 1

January 27, 1989

DCT Board Restores Funding to Rosenberg’s Lymphocyte Projects

June 17, 1994